Related Experiment Video
Updated: Jul 11, 2026
14:26
A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
Missed symptoms of menopause
1Department of OB/GYN, Columbia University Medical Center, New York, NY 10032, USA. mpw1@columbia.edu
International Journal of Clinical Practice
|September 26, 2007
Summary
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) show limited evidence for improving common menopause symptoms like mood and sleep disturbances. More research is needed to confirm their effectiveness compared to placebo.
Area of Science:
- Reproductive Medicine
- Neuroscience
- Pharmacology
Background:
- Menopause significantly impacts quality of life for many women.
- Vasomotor symptoms (VMS) are common, but 'missed symptoms' like mood changes and sleep disturbances also affect roughly half of menopausal women.
- Declining estrogen levels may influence neurotransmitter pathways implicated in these symptoms.
Purpose of the Study:
- To review available data on the efficacy of SSRIs and SNRIs.
- To assess their effectiveness in treating commonly overlooked menopausal symptoms.
- To determine if these antidepressants are viable alternatives to hormone therapy.
Main Methods:
- Systematic review of existing clinical studies.
- Analysis of placebo-controlled trials.
- Examination of data on SSRI and SNRI efficacy for mood and sleep disturbances during menopause.
Main Results:
- Pilot studies suggest potential benefits of some SSRIs and SNRIs for menopausal mood and sleep.
- Limited studies show significant improvement over placebo.
- Venlafaxine (an SNRI) improved mood; citalopram and paroxetine (SSRIs) improved sleep in single trials.
Conclusions:
- SSRIs and SNRIs may offer some relief for menopausal mood and sleep issues.
- Current evidence is not robust, with few significant placebo-controlled trial results.
- Further rigorous trials are necessary to establish SSRIs/SNRIs as effective treatments for non-VMS menopausal symptoms.
Related Concept Videos
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:24Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:19The Menstrual Cycle
The menstrual cycle is a recurrent sequence of changes in the uterine endometrium, specifically its functional layer, the stratum functionalis. This cycle prepares the uterus for potential pregnancy. This cycle typically spans 21–35 days, averaging 28 days, and aligns with the ovarian cycle, regulated by fluctuating levels of ovarian hormones, primarily estrogen and progesterone.
The menstrual phase occurs from days 1 to 5 and involves the shedding of the stratum functionalis, as a uterine...
The menstrual phase occurs from days 1 to 5 and involves the shedding of the stratum functionalis, as a uterine...
01:18Menses Phase
The uterine cycle begins with the menstrual phase, which is considered day one of the cycle and typically lasts about five days. This phase is characterized by the degeneration and shedding of the stratum functionalis, the functional layer of the endometrium.
When fertilization does not occur, the corpus luteum deteriorates, causing a significant drop in the levels of estrogen and progesterone in the body. This hormonal decrease triggers the release of prostaglandins, which cause the uterine...
When fertilization does not occur, the corpus luteum deteriorates, causing a significant drop in the levels of estrogen and progesterone in the body. This hormonal decrease triggers the release of prostaglandins, which cause the uterine...
01:22Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.